Aptevo Therapeutics, a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company was spun off from Emergent BioSolutions Inc. in 2016 and is based in Seattle, Washington.
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.
New Bispecific Therapeutic Candidate APVO442 uses ADAPTIR-FLEX Platform TechnologyAPVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the Treatment of Prostate CancerSEATTLE, WA / ACCESSWIRE / December 2, 2020 / Aptevo Therapeutics Inc.
This Bi Syndrome Treatment report provides complete analysis of the market on global and regional level. It inspects the development rate and the market value dependent on the market elements and growth initiating factors. The market players